Name: Q&A: Poolbeg Pharma CEO Jeremy Skillington on its groundbreaking AI collaboration
Uploaded: 2023-06-29T10:01:51.747449+00:00
Duration: 353 s
Channel: Vox Markets

Vox Markets

Jeremy Skillington, CEO of Poolbeg Pharma, talks us through the results of its successful collaboration with leading AI specialist CytoReason, making at a pioneer in AI-enabled drug discovery.

0:28 Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.
2:07 How the approach to analyse human challenge data for influenza with AI is the first of its kind.
3:28 Next steps after the successful conclusion of the collaboration, moving towards partnership.
4:54 Why Poolbeg is at the forefront of AI-enabled drug discovery

Jeremy Skillington, CEO of Poolbeg Pharma, talks us through the results of its successful collaboration with leading AI specialist CytoReason, making at a pioneer in AI-enabled drug discovery.0:28 Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment. 2:07 How the approach to analyse human challenge data for influenza with AI is the first of its kind. 3:28 Next steps after the successful conclusion of the collaboration, moving towards partnership. 4:54 Why Poolbeg is at the forefront of AI-enabled drug discovery

Discussing the results of the successful collaboration with AI-specialist CytoReason to study human challenge data for influenza, including validation of Poolbeg’s POLB001 treatment.

How the approach to analyse human challenge data for influenza with AI is the first of its kind.

Next steps after the successful conclusion of the collaboration, moving towards partnership

Why Poolbeg is at the forefront of AI-enabled drug discovery

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/005/931/005931/video_hgDShhF.mp4